Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2016 Aug;42(3):407-17. doi: 10.1016/j.rdc.2016.03.001. Epub 2016 Jun 21.

Use of Biologics in Sjögren's Syndrome.

Author information

1
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France.
2
Department of Rheumatology, CHRU Brest, rue Boulevard Tanguy Prigent, 29609 Brest, France; EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, 5 Foch - CHU Morvan - BP 824, 29609 Brest, France.
3
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France. Electronic address: xavier.mariette@aphp.fr.

Abstract

The management of patients suffering from primary Sjögren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking. However, progress made in the understanding of pSS pathogenesis has allowed moving into a more targeted approach to therapeutic intervention. Given the key role of chronic B-cell activation, B-cell target therapies were the first candidates. New pathways are currently being investigated, including costimulation and ectopic germinal center. In this review, we summarize the current evidence regarding B-cell targeted and anti-TNF therapies and provide an overview of promising drugs in the pipeline.

KEYWORDS:

Biological treatment; B cell; Clinical trials; Outcome measure; Primary Sjögren’s syndrome

PMID:
27431344
DOI:
10.1016/j.rdc.2016.03.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center